

Allosteric ligand subpocket of S1P₅ as a determinant of inverse agonism and ligand specificity

Lyapina E.^{1*}, Marin E.¹, Gusach A.¹, Orekhov Ph.¹, Gerasimov A.², Luginina A.¹, Vakhrameev D.¹, Kovaleva M.¹, Khusainov G.¹, Khorn P.¹, Shevtsov M.¹, Kovalev K.¹, Okhrimenko I.¹, Popov P.¹, Gushchin I.¹, Rogachev A.^{1,3}, Gordeliy V.^{1,4}, Borshchevskiy V.¹, Mishin A.¹, Cherezov V.^{1,5}

¹ *Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology, Dolgoprudny, Russia*

² *Vyatka State University, Kirov, Russia*

³ *Joint Institute for Nuclear Research, Dubna, Russia*

⁴ *Institut de Biologie Structurale (IBS), Université Grenoble Alpes, CEA, CNRS, Grenoble, France*

⁵ *Bridge Institute, Department of Chemistry, University of Southern California, Los Angeles, USA*

* *elizaveta0503@gmail.com*

Key words: GPCR, S1P₅, X-ray structure, inverse agonist

Motivation and Aim: S1P is a bioactive lysophospholipid targeting GPCRs. It acts via five different subtypes of S1P receptors (S1PR)—S1P₁₋₅. Despite sequence similarity, these receptors differ in expression profiles: S1P₁₋₃ receptors are abundant, S1P₄ is limited to the immune system, and S1P₅ is mainly present in nervous and immune systems. The last one regulates cell migration for NK cells and oligodendrocyte progenitors, playing a role in autoimmune, neurodegenerative and oncogenic disorders. Although FDA approved multiple non-selective (fingolimod) or dual S1P₁/S1P₅ agonists, few selective modulators were available until the last year. Lack of these modulators leads to constraints in S1P₅ signaling research. To speed up the design of S1P₅ ligands, an inactive structure of this receptor can contribute.

Methods: Optimized for insect cell expression, the human *S1PR5* gene was fused with a partner protein in the 3rd intracellular loop, expression tags on N-term, and a C-term cleavable decahistidine tag. This construct was expressed in Sf9 cells using the baculovirus expression system, purified with metal-affinity chromatography and co-crystallized in the lipid cubic phase with an inverse agonist. The crystals undergone room temperature serial femtosecond crystallography (SFX) data collection at Pohang Accelerator Laboratory X-Ray Free-Electron Laser (PAL-XFEL) in South Korea.

Results: The crystal structure was solved at a 2.2 Å resolution in the P2₁2₁2₁ space group with identical unit cell constants as the single-crystal data. The receptor crystallized with two monomers per asymmetric unit, forming an antiparallel dimer through the TM4-TM4 interface. The structure shares the classical Edg-receptor architecture with seven transmembrane helices bundle, N-terminal and C-terminal helices. Receptor's microswitches conformations correspond to inactive position, indirectly locked by the ligand.

Conclusions: This inactive-state structure of S1P₅ in a complex with an inverse agonist. It reveals an uncommon allosteric binding mode of ligand targeting the variable subpocket of an S1PR and displays the way to design inverse agonists.

Acknowledgements: The work was supported by the Russian Ministry of Science and Higher Education grant No. 075-15-2021-1354.